BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18318736)

  • 1. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Huang YH; Su CW; Lin HC; Chiang JH; Chiou YY; Huo SC; Lee PC; Lee SD
    Clin Transplant; 2008; 22(4):469-75. PubMed ID: 18318736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy.
    Huo TI; Wu JC; Lin HC; Lee FY; Hou MC; Huang YH; Lee PC; Chang FY; Lee SD
    Liver Transpl; 2004 Dec; 10(12):1507-13. PubMed ID: 15558587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
    Yao FY; Bass NM; Ascher NL; Roberts JP
    Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
    Yao FY; Bass NM; Nikolai B; Merriman R; Davern TJ; Kerlan R; Ascher NL; Roberts JP
    Liver Transpl; 2003 Jul; 9(7):684-92. PubMed ID: 12827553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.
    Maddala YK; Stadheim L; Andrews JC; Burgart LJ; Rosen CB; Kremers WK; Gores G
    Liver Transpl; 2004 Mar; 10(3):449-55. PubMed ID: 15004776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
    Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
    Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.
    Lu DS; Yu NC; Raman SS; Lassman C; Tong MJ; Britten C; Durazo F; Saab S; Han S; Finn R; Hiatt JR; Busuttil RW
    Hepatology; 2005 May; 41(5):1130-7. PubMed ID: 15841454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
    Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
    Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
    Park SJ; Freise CE; Hirose R; Kerlan RK; Yao FY; Roberts JP; Vagefi PA
    Clin Transplant; 2012; 26(4):E359-64. PubMed ID: 22693962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Lin HC; Huang YH; Wu JC; Chiang JH; Lee PC; Lee SD
    Cancer; 2006 Jul; 107(1):141-8. PubMed ID: 16708358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The best candidates for transarterial chemotherapy in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times.
    Jang JW; Choi JY; Bae SH; Kim CW; Cho SH; Yoon SK; Yang JM; Han JY; Lee YS; Kim DG
    Aliment Pharmacol Ther; 2007 Jul; 26(1):87-94. PubMed ID: 17555425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
    Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
    J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
    Ioannou GN; Perkins JD; Carithers RL
    Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.
    Cucchetti A; Cescon M; Bigonzi E; Piscaglia F; Golfieri R; Ercolani G; Cristina Morelli M; Ravaioli M; Daniele Pinna A
    Liver Transpl; 2011 Nov; 17(11):1344-54. PubMed ID: 21837731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era.
    Porrett PM; Peterman H; Rosen M; Sonnad S; Soulen M; Markmann JF; Shaked A; Furth E; Reddy KR; Olthoff K
    Liver Transpl; 2006 Apr; 12(4):665-73. PubMed ID: 16482577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis.
    Cucchetti A; Ercolani G; Vivarelli M; Cescon M; Ravaioli M; La Barba G; Zanello M; Grazi GL; Pinna AD
    Liver Transpl; 2006 Jun; 12(6):966-71. PubMed ID: 16598792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era.
    Ravaioli M; Grazi GL; Ercolani G; Cescon M; Del Gaudio M; Zanello M; Ballardini G; Varotti G; Vetrone G; Tuci F; Lauro A; Ramacciato G; Pinna AD
    Transplantation; 2006 Feb; 81(4):525-30. PubMed ID: 16495798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation.
    Lao OB; Weissman J; Perkins JD
    Clin Transplant; 2009; 23(6):874-81. PubMed ID: 19453644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.